Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

Excellergy

9 posts
NNovartis
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Read More

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

  • 2026-04-17
Novartis Pharma AG – Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases   – Lead…
NNovartis
Assessing Novartis (SWX:NOVN) Valuation After Positive Phase III Data And Upcoming Regulatory Milestones
Read More

Novartis Excellergy Deal Highlights Push Into Allergy Biologics And Returns

  • 2026-04-08
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Novartis…
NNovartis
Assessing Novartis (SWX:NOVN) Valuation After Positive Phase III Data And Upcoming Regulatory Milestones
Read More

Novartis Excellergy Deal Highlights Push Into Allergy Biologics And Returns

  • 2026-04-02
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Novartis…
NNovartis
Novartis strikes $3 billion deal for experimental cancer therapy
Read More

Novartis strikes up to $2 billion deal for Excellergy

  • 2026-03-30
Swiss drugmaker Novartis has agreed to acquire California-based biotech firm Excellergy in a deal worth up to US$2…
NNovartis
Novartis strikes $3 billion deal for experimental cancer therapy
Read More

Novartis strikes up to $2 billion deal for Excellergy

  • 2026-03-29
Swiss drugmaker Novartis has agreed to acquire California-based biotech firm Excellergy in a deal worth up to US$2…
NNovartis
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy
Read More

Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy

  • 2026-03-27
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy Proactive uses images sourced from Shutterstock Novartis…
NNovartis
Novartis logo
Read More

Novartis acquires Excellergy for $2 billion

  • 2026-03-27
Novartis today announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company…
NNovartis
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
Read More

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

  • 2026-03-27
– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases     – Lead asset…
NNovartis
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
Read More

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

  • 2026-03-27
– Acquisition brings together Excellergy’s differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of…
Switzerland
www.europesays.com